Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P04075
UPID:
ALDOA_HUMAN
Alternative names:
Lung cancer antigen NY-LU-1; Muscle-type aldolase
Alternative UPACC:
P04075; B4DXI7; Q6FH76; Q6FI10; Q96B15; Q9BWD9; Q9UCN2
Background:
Fructose-bisphosphate aldolase A, also known as Muscle-type aldolase, plays a pivotal role in glycolysis and gluconeogenesis by catalyzing the conversion of beta-D-fructose 1,6-bisphosphate into two triose phosphates. Its alternative names include Lung cancer antigen NY-LU-1, highlighting its diverse biological significance.
Therapeutic significance:
Linked to Glycogen storage disease 12, a metabolic disorder characterized by increased hepatic glycogen and hemolytic anemia, Fructose-bisphosphate aldolase A's study could lead to innovative treatments for metabolic diseases.